# EDGAR Filing Document

**Accession Number:** 0001553846
**File Stem:** 0001178913-25-003530
**Filing Date:** 2025-10
**Character Count:** 9703
**Document Hash:** 899aedb9ffaca886c43d9cc579baa6c6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-25-003530.hdr.sgml**: 20251021

**ACCESSION NUMBER**: 0001178913-25-003530

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251021

**FILED AS OF DATE**: 20251021

**DATE AS OF CHANGE**: 20251021

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RedHill Biopharma Ltd.
- **CENTRAL INDEX KEY:** 0001553846
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35773
- **FILM NUMBER:** 251405338

**BUSINESS ADDRESS:**
- **STREET 1:** 21 HA'ARBA'A STREET
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 64739
- **BUSINESS PHONE:** 972-3-541-3131

**MAIL ADDRESS:**
- **STREET 1:** 21 HA'ARBA'A STREET
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 64739

------

**UNITED STATES** 

SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549
FORM 6-K

#### Report of Foreign Private Issuer

#### Pursuant to Rule 13a-16 or 15d-16

#### of the Securities Exchange Act of 1934
For the month of October 2025

Commission File No.:001-35773

REDHILL BIOPHARMA LTD.

(Translation of registrant's name into English)

#### 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

------

#### Entry into Amendment to Any Market Purchase Agreement with Alumni Capital LP
As previously reported, on June 20, 2025, RedHill Biopharma Ltd. (the "**Company**") entered into an Any Market Purchase Agreement (the "**Purchase Agreement**") with Alumni Capital LP, a Delaware limited partnership (the "**Purchaser**"). Pursuant to the Purchase Agreement, the Company has the right, but not the obligation, to sell to the Purchaser, from time to time, up to $10,000,000 of American Depositary Shares ("**ADSs**"), each representing 10,000 ordinary shares, par value NIS 0.01 per share, of the Company, subject to the terms and conditions set forth in the Purchase Agreement.

The Purchase Agreement provides for different types of purchase notices (the "**Purchase Notices**") that the Company may deliver to the Purchaser, each with different terms of purchase of ADSs. As one type of Purchase Notice, the Company may, at its discretion, direct the Purchaser ("**Forward Purchase Notice**") to purchase the number of ADSs having an aggregate purchase price equal to the lesser of $500,000 or thirty percent (30%) of the trading volume of the ADSs beginning at 4:00 a.m. New York time on the Purchase Notice Date and ending at the time on the date the Company delivers the Purchase Notice ("**Purchase Notice Date**") that the Forward Purchase Notice has been received by email by the Company, at a price equal to the lowest traded price of the ADSs on the Purchase Notice Date with respect to a Forward Purchase Notice multiplied by 96%.

The Purchase Agreement prohibits us from directing the Purchaser to purchase any ADSs (i) if those ADSs, when aggregated with all other ADSs then held or beneficially owned by the Purchaser and its affiliates, would result in the Purchaser and its affiliates holding or having beneficial ownership, at any single point in time, of more than 4.99% of the number of ADSs outstanding immediately after the issuance of securities issuable pursuant to a Purchase Notice, or (ii) where the issuance of such ADSs, when aggregated with all other ADSs and Ordinary Shares then held or beneficially owned by the Purchaser and its affiliates, would result in the Purchaser and its affiliates holding or having beneficial ownership, at any single point in time, of more than 4.99% of the Company's issued share capital or voting rights in it (unless and until the Company obtains the approval of its shareholders for the issuance of ADSs in excess of such amount), in either case subject to the option to issue Prefunded Warrants in lieu of ADSs with respect to the sales pursuant to the Initial Purchase Notice or any Regular Purchase Notice.

The Company and the Purchaser have entered into an amendment to the Purchase Agreement providing that the 4.99% ownership limits described above are changed to be 9.99% ownership limits but only with respect to Forward Purchase Notices delivered under the Purchase Agreement.

The foregoing description of the amendment to the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the amendment, which is filed as Exhibit 1.1 to this Report on Form 6-K and is incorporated herein by reference.

------

#### Exhibit Index

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [1.1](exhibit_1-1.htm) | [Amendment to Market Purchase Agreement, dated as of October 20, 2025.](exhibit_1-1.htm) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | REDHILL BIOPHARMA LTD. | REDHILL BIOPHARMA LTD. |
|  | (the "**Registrant**") | (the "**Registrant**") |
| Date: October 21, 2025 | By: | /s/ Dror Ben-Asher |
|  | Name: | Dror Ben-Asher |
|  | Title: | Chief Executive Officer |

---

------

## Ex-99

------

#### Exhibit 1.1

#### SIDE LETTER AGREEMENT
This Side Letter Agreement (this "**Side Letter Agreement**"), dated as of October 20, 2025, is by and between Redhill Biopharma Ltd. (the "**Company**") and Alumni Capital LP ("**Alumni**"). The Company and Alumni are collectively referred to herein as the "**Parties**".

WHEREAS, on June 20, 2025, the Company entered into that certain Any Market Purchase Agreement (the "**Agreement**") with Alumni, pursuant to which, among other things, the Company has the right, but not the obligation, to sell to Alumni, from time to time, up to $10,000,000 of American Depositary Shares ("**ADSs**"), each representing 10,000 ordinary shares ("**Ordinary Shares**"), par value NIS 0.01 per share, of the Company, subject to the terms and conditions set forth in the Agreement; and

WHEREAS, the Company and Alumni desire to enter into this Side Letter Agreement to amend certain provisions of the Agreement as set forth herein.

In consideration of the mutual agreements contained herein, the Parties hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Definitions</u>. Unless otherwise specified, capitalized terms used herein but not otherwise defined herein shall have the respective meanings given such terms in the Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Amendment of Section 8.2(f) of the Agreement</u>. The parties hereby agree the sentence beginning with "The "**<u>Beneficial Ownership Limitation</u>**" and ending with "pursuant to a Purchase Notice" within Section 8.2(f) of the Agreement shall be amended to read in its entirety as follows:

The "**<u>Beneficial Ownership Limitation</u>**" shall be (i) 9.99% of the voting power of the Company or of the number of Ordinary Shares and ADSs outstanding immediately after the issuance of Purchase Notice Securities issuable pursuant to a Forward Purchase Notice and (ii) 4.99% of the voting power of the Company or of the number of Ordinary Shares and ADSs outstanding immediately after the issuance of Purchase Notice Securities issuable pursuant to a Regular Purchase Notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Confirmation</u>. Except as set forth herein, all other provisions of the Agreement shall remain unmodified by this Side Letter Agreement, and shall remain in fully force and effect in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Counterparts</u>. For the convenience of the parties, this Side Letter Agreement may be executed in multiple counterparts, each of which for all purposes shall be deemed to be an original, and all such counterparts shall together constitute but one and the same agreement. Delivery of an executed counterpart of a signature page of this Agreement by telecopy, e-mail, facsimile or other electronic means shall be effective as a delivery of a manually executed counterpart of this Side Letter Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Governing Law</u>. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE AND APPLICABLE UNITED STATES FEDERAL LAW

[*Signature page follows*.]

------

IN WITNESS WHEREOF, the undersigned have executed and delivered this Side Letter Agreement as of the date first above written.

---

| | |
|:---|:---|
| **REDHILL BIOPHARMA LTD** | **REDHILL BIOPHARMA LTD** |
| By: | */s/ Dror Ben-Asher* |
| Name: Dror Ben-Asher<br> Title: CEO | Name: Dror Ben-Asher<br> Title: CEO |

---

---

| | |
|:---|:---|
| **ALUMNI CAPITAL LP**<br>By: Alumni Capital GP LLC | **ALUMNI CAPITAL LP**<br>By: Alumni Capital GP LLC |
| By: | */s/ Ashkan Mapar* |
| Name: Ashkan Mapar<br> Title: General Manager | Name: Ashkan Mapar<br> Title: General Manager |

---

------